Greg joined Sangamo Therapeutics in 2020 as Vice President of Genome Engineering. He leads teams responsible for the discovery and optimization of novel zinc finger proteins (ZFPs), enabling their translation into genomic medicines. Greg has spent over 20 years in academia and biotech, working in the areas of genome editing, cell engineering, and directed protein evolution. In 2004 at Sigma-Aldrich, Greg’s team collaborated with the lab of Alan Lambowitz (Univ. Of Texas, Austin) to develop RNA-guided systems for bacterial genome editing based on group II introns (retrotransposons). From 2007 onward, his team worked in partnership with Sangamo to develop and deploy ZFN synthesis processes supporting the world’s first genome editing reagents for human somatic cell research in academia, biotech, and pharma. During this time, his team spearheaded a widely adopted method which uses ssDNA oligos to edit human genomic DNA near ZFN-induced double strand breaks (Chen et al., Nature Methods, 2011:753), as well as methods for reducing chromatin impacts on CRISPR systems (Chen et al., Nature Communications, 2017: 1-12). Greg received his B.S. in Chemical Engineering at the University of Texas, Austin and his Ph.D. in Chemical Engineering at the University of Oklahoma, Norman.